Self-copying RNA vaccine wins first full approval: what’s next?
Elie Dolgin • December 6, 2023
Researchers look ahead to the potential uses and benefits of a technology that has been more than 20 years in the making.
The approval of yet another RNA-based vaccine for COVID-19 might not seem momentous. But the endorsement last week by Japanese authorities of a jab against SARS-CoV-2 constructed using a form of RNA that can make copies of itself inside cells — the first ‘self-amplifying’ RNA (saRNA) granted full regulatory approval anywhere in the world — marks a pivotal advance.
The new vaccine platform could provide potent defence against various infectious diseases and cancers. And because it could be used at a lower dose, it might have fewer side effects than other messenger RNA (mRNA) treatments have.
Continue reading at Nature.
Pixels meet paint, as a digital “mask” conceals damage on a 15th-century painting.
Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or availability.